In certain cancers, such as nasopharyngeal carcinoma (NPC), the density of TAMs correlates with higher PD-L1 expression on tumor cells [376], suggesting that targeting PD-L1 on TAMs (and not necessarily on tumor cells) may facilitate therapeutic response to checkpoint inhibitors. The gene discussed is CD274; the disease is cancer.